GenVec, Inc.
Gaithersburg, MD, US· latest recorded location
GenVec, Inc. is named on 89 US grants and 107 published applications in this corpus. Its most frequent classification is C12N (Microorganisms or enzymes).
- Granted patents
- 89
- Published applications
- 107
- Inventors
- 66
- Granted in 2026 so far
- 0
- Most recent grant
- 14 Jun 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 6 | 0 |
| 1999 | 4 | 0 |
| 2000 | 5 | 0 |
| 2001 | 5 | 4 |
| 2002 | 11 | 13 |
| 2003 | 10 | 19 |
| 2004 | 6 | 5 |
| 2005 | 5 | 6 |
| 2006 | 3 | 2 |
| 2007 | 2 | 5 |
| 2008 | 0 | 4 |
| 2009 | 0 | 6 |
| 2010 | 0 | 1 |
| 2011 | 0 | 4 |
| 2012 | 1 | 5 |
| 2013 | 1 | 1 |
| 2014 | 2 | 5 |
| 2015 | 1 | 4 |
| 2016 | 2 | 3 |
| 2017 | 8 | 4 |
| 2018 | 4 | 6 |
| 2019 | 3 | 7 |
| 2020 | 4 | 0 |
| 2021 | 3 | 3 |
| 2022 | 2 | 0 |
By publication year.
Technology areas
Share of 196 documents
- C12NMicroorganisms or enzymes180
- A61KMedicines and medical preparations144
- C07KPeptides107
- A61PTherapeutic uses of medicines96
- Y02ATechnologies for adaptation to climate change19
- C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms9
- G01NInvestigating or analysing materials by determining their chemical or physical properties8
- Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests6
- B01DSeparation5
- B01JChemical or physical processes5
Recent patents
- Simian (gorilla) adenovirus or adenoviral vectors and methods of use14 Jun 2022US 11,359,214 B2
- Adenoviral vector encoding human atonal homolog-1 (HATH1)22 Mar 2022US 11,279,951 B2
- Adenovectors for delivery of therapeutic genetic material into T cells26 Oct 2021US 11,155,832 B2
- Affenadenovirus (gorilla) or adenoviral vectors and methods of use15 Jun 2021US 11,034,975 B2
- Modified serotype 28 adenoviral vectors16 Mar 2021US 10,947,560 B2
- Adenovectors for delivery of therapeutic genetic material into t cells30 Sep 2021US 2021/0301303 A1
- Modified serotype 28 adenoviral vectors2 Sep 2021US 2021/0269827 A1
- Simian (gorilla) adenovirus or adenoviral vectors and methods of use11 Feb 2021US 2021/0040502 A1
- Affenadenovirus (gorilla) or adenoviral vectors and methods of use17 Oct 2019US 2019/0316152 A1
- Affenadenovirus (gorilla) or adenoviral vectors and methods of use5 Sep 2019US 2019/0269794 A1
Most cited
By later US patents
- Stocks of recombinant, replication-deficient adenovirus free of replication-competent adenovirus184US 5,994,106 A1999
- Targeting adenovirus with use of constrained peptide motifs158US 5,846,782 A1998
- Penton base protein and methods of using same136US 5,559,099 A1996
- Complementary adenoviral systems and cell lines125US 5,851,806 A1998
- Methods and vectors for site-specific recombination109US 5,801,030 A1998